SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
← catalyst calendarSponsored by Scholar Rock, Inc. (industry) · SRRK — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
112actual
Sites
22
Countries
South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-04-23 | actual | When the study began enrolling |
| Primary completion | 2025-04-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-14 | actual | The whole study's end, after follow-up |
| First posted | 2020-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Interventions
- Biological: SRK-181
- Biological: anti-PD-(L)1 antibody therapy
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of single agent SRK-181
measured The first 21 days of study treatment
Safety and tolerability of SRK-181 in combination with anti-PD-(L)1 antibody therapy
measured The first 21 days of study treatment
Publications
- PMID 41530380 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SRRK's whole pipeline · Catalyst calendar · Every registered study · What changed